Predictive value of the bone markers osteocalcin and C-terminal telopeptide for jaw osteonecrosis in high-risk prostate cancer patients on bisphosphonate therapy: A prospective study.

CONCLUSION: Our study demonstrated no clear association between the levels of serum OC and CTX and bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, there is no clinically useful biomarker for the prediction of jaw osteonecrosis. More studies are needed using different bone turnover markers in order to identify patients at risk for BRONJ. PMID: 31697256 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Related Links:

ConclusionsIn the Japanese ERA 223 subgroup, concurrent treatment with AAP and radium-223 did not significantly improve SSE-FS and increased the incidence of fracture, similar to outcomes achieved in the overall population, while an increased incidence of death was not evident. The combination of radium-223 with AAP is not recommended in Japanese patients with asymptomatic or mildly symptomatic mCRPC and bone metastases.Clinical trial registrationClinical trial registration no: NCT02043678.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Metastatic Castration Resistant Prostate Cancer Interventions:   Drug: Rucaparib;   Drug: Enzalutamide;   Drug: Abiraterone Sponsor:   Clovis Oncology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Although Olaparib (Ola, a PARP-inhibitor), in combination with other chemotherapeutic agents, was clinically approved to treat prostate cancer, but cytotoxicity, off-target effects of DNA damaging agents limit its applications in clinic. To improve the anti-cancer activity and to study the detailed mechanism of anti-cancer action, here we have used bioactive compound curcumin (Cur) in combination with Ola. Incubation of Ola in Cur pre-treated cells synergistically increased the death of oral cancer cells at much lower concentrations than individual optimum dose and inhibited the topoisomerase activity. Sh...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
BASEL, Switzerland, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 HERO...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
Publication date: November 2019Source: Journal of Comparative Pathology, Volume 173Author(s): T.H.M. Vargas, L.H. Pulz, D.G. Ferro, R.A. Sobral, M.A.F.A. Venturini, H.L. Corrêa, R.F. StrefezziSummaryMalignant melanomas (MMs) represent 7% of all malignant neoplasms in dogs. Oral melanocytic neoplasms are often malignant and associated with poor prognosis. There are no universally accepted prognostic markers for canine oral melanoma. Galectin (Gal)-3 is a prognostic marker for human neoplasms such as thyroid, gastric, colorectal and prostate cancers. The protein is related to processes that favour cancer progression, s...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
Publication date: Available online 1 November 2019Source: Preventive MedicineAuthor(s): Jan M. Eberth, Whitney E. Zahnd, Swann Arp Adams, Daniela B. Friedman, Stephanie B. Wheeler, James R. HébertAbstractThe mortality-to-incidence ratio (MIR) can be computed from readily accessible, public-use data on cancer incidence and mortality, and a high MIR value is an indicator of poor survival relative to incidence. Newly available data on congressional district-specific cancer incidence and mortality from the U.S. Cancer Statistics (USCS) database from 2011 to 2015 were used to compute MIR values for overall (all types com...
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
More News: Biochemistry | Cancer | Cancer & Oncology | Oral Cancer | Prostate Cancer | Reclast | Study | Urology & Nephrology | Zometa